title: Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
abstract: Approximately 100 million newborn children receive Bacille Calmette-Guérin (BCG) annually, because vaccination is consistently protective against childhood tuberculous meningitis and miliary TB. By contrast, BCG efficacy against pulmonary TB in children and adults is highly variable, ranging from 0% to 80%, though it tends to be higher in individuals who have no detectable prior exposure to mycobacterial infections, as judged by the absence of delayed-type hypersensitivity response (a negative tuberculin skin test, TST). The duration of protection against pulmonary TB is also variable, but lasts about 10 years on average. These observations raise the possibility that BCG revaccination, following primary vaccination in infancy, could be efficacious among TST-negative adolescents as they move into adulthood, the period of highest risk for pulmonary disease. To inform continuing debate about revaccination, this paper assesses the effectiveness and cost-effectiveness of revaccinating adolescents in a setting with intense transmission-Cape Town, South Africa. For a cost of revaccination in the range US$1-10 per person, and vaccine efficacy between 10% and 80% with protection for 10 years, the incremental cost per year of healthy life recovered (disability-adjusted life years, DALY) in the vaccinated population lies between US$116 and US$9237. The intervention is about twice as cost-effective when allowing for the extra benefits of preventing transmission, with costs per DALY recovered in the range US$52-$4540. At 80% efficacy, revaccination averted 17% of cases. Under the scenarios investigated, BCG revaccination is cost-effective against international benchmarks, though not highly effective. Cost-effectiveness ratios would be more favourable if we also allow for TB cases averted by preventing transmission to HIV-positive people, for the protection of HIV-negative people who later acquire HIV infection, for the possible non-specific benefits of BCG, for the fact that some adolescents would receive BCG for the first time, and for cost sharing when BCG is integrated into an adolescent immunization programme. These findings suggest, subject to further evaluation, that BCG revaccination could be cost-effective in some settings.
authors.affiliation: World Health Organization, Avenue Appia, CH1211 Geneva 27, Switzerland. dyec@who.int
authors.forename: Christopher
authors.initials: C
authors.lastname: Dye
mesh_terms: D000293:Adolescent; D001500:BCG Vaccine / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs / Q000191:economics; D007117:Immunization, Secondary; D008962:Models, Theoretical; D013019:South Africa; D014376:Tuberculosis / Q000517:prevention & control* / Q000635:transmission
chemical_list: D001500:BCG Vaccine
keywords: Bacille Calmette–Guérin; adolescents; cost-effectiveness; immunization; revaccination; tuberculosis
references.citation: Lancet. 2013 Mar 23;381(9871):972-4
references.pmid: 23391464
references.citation: Parasitol Today. 1994 Dec;10(12):489-93
references.pmid: 15275519
references.citation: Wkly Epidemiol Rec. 2007 May 25;82(21):193-6
references.pmid: 17526121
references.citation: Lancet. 2005 Oct 22-28;366(9495):1443-51
references.pmid: 16243089
references.citation: Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93
references.pmid: 16973982
references.citation: Wkly Epidemiol Rec. 2004 Jan 23;79(4):27-38
references.pmid: 14768305
references.citation: Thorax. 2010 Dec;65(12):1067-71
references.pmid: 21030395
references.citation: Tubercle. 1982 Dec;63(4):255-68
references.pmid: 6763793
references.citation: Lancet. 2006 Apr 8;367(9517):1173-80
references.pmid: 16616560
references.citation: Wkly Epidemiol Rec. 1995 Aug 11;70(32):229-31
references.pmid: 7669527
references.citation: Lancet. 1998 Dec 12;352(9144):1886-91
references.pmid: 9863786
references.citation: Vaccine. 2011 Jul 12;29(31):4875-7
references.pmid: 21616115
references.citation: BMJ. 2011 Sep 29;343:d5974
references.pmid: 21964347
references.citation: Int J Tuberc Lung Dis. 2010 Apr;14(4):406-12
references.pmid: 20202297
references.citation: Lancet. 2013 Mar 23;381(9871):1021-8
references.pmid: 23391465
references.citation: BMC Infect Dis. 2011 Jun 01;11:156
references.pmid: 21631918
references.citation: JAMA. 2004 May 5;291(17):2086-91
references.pmid: 15126436
references.citation: Epidemiol Infect. 1997 Oct;119(2):183-201
references.pmid: 9363017
references.citation: BMJ. 2008 Nov 13;337:a2052
references.pmid: 19008268
references.citation: JAMA. 2004 May 5;291(17):2127-8
references.pmid: 15126443
references.citation: Clin Infect Dis. 2012 Mar;54(6):784-91
references.pmid: 22267721
references.citation: Indian J Med Res. 2006 Feb;123(2):103-6
references.pmid: 16575105
references.citation: PLoS One. 2011;6(10):e25098
references.pmid: 22016763
references.citation: BMJ. 2005 Dec 10;331(7529):1364
references.pmid: 16282379
references.citation: Lancet. 1996 Jul 6;348(9019):17-24
references.pmid: 8691924
references.citation: BMC Public Health. 2013 Mar 11;13:220
references.pmid: 23497196
references.citation: Int J Tuberc Lung Dis. 2005 Oct;9(10):1171-3
references.pmid: 16229231
references.citation: Bull World Health Organ. 2003;81(8):573-80
references.pmid: 14576889
references.citation: Int J Epidemiol. 2004 Jun;33(3):477-84
references.pmid: 15020565
references.citation: Vaccine. 2013 Jun 26;31(30):3098-103
references.pmid: 23583897
references.citation: Lancet. 1994 Nov 5;344(8932):1245-9
references.pmid: 7967984
references.citation: BMC Public Health. 2013 May 21;13:493
references.pmid: 23692596
references.citation: Indian J Med Res. 2006 Feb;123(2):119-24
references.pmid: 16575109
references.citation: J Infect Dis. 2011 Jun 1;203(11):1582-9
references.pmid: 21592987
references.citation: PLoS Med. 2011 Mar;8(3):e1001012
references.pmid: 21445325
references.citation: Tuberculosis (Edinb). 2006 Nov;86(6):397-403
references.pmid: 16901755
references.citation: Thorax. 2013 Mar;68(3):263-8
references.pmid: 23019256
references.citation: Int J Tuberc Lung Dis. 2001 Aug;5(8):717-23
references.pmid: 11495262
references.citation: Trop Med Int Health. 2009 Feb;14(2):136-42
references.pmid: 19236665
references.citation: Lancet Infect Dis. 2012 Apr;12(4):300-6
references.pmid: 22071248
references.citation: Am J Respir Crit Care Med. 2011 Jan 1;183(1):88-95
references.pmid: 20802162